SCHEMBL6236131

SCHEMBL6236131

Cc1ncccc1COc1ccc(S(=O)(=O)N2CCN(C)C(C)C2C(=O)NO)cc1

nearest known ligand 0.81

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 17/20 0.81
MMP1 P03956 15/20 0.81
MMP13 P45452 13/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6241545 0.91 ADAM17 (0.81) ADAM17MMP1MMP13
SCHEMBL6238137 0.90 ADAM17 (1.00) ADAM17MMP1MMP13
SCHEMBL6241559 0.89 ADAM17 (1.00) ADAM17MMP1MMP13
SCHEMBL6234528 0.85 ADAM17 (0.81) ADAM17MMP1MMP13
SCHEMBL6242400 0.85 ADAM17 (0.81) ADAM17MMP1MMP13
SCHEMBL6240343 0.84 ADAM17 (0.80) ADAM17MMP1MMP13
SCHEMBL6237689 0.83 ADAM17 (0.67) ADAM17MMP1MMP13
SCHEMBL7135335 0.83 ADAM17 (0.67) ADAM17MMP1MMP13
SCHEMBL6244488 0.83 ADAM17 (0.66) ADAM17MMP1MMP13
SCHEMBL6234714 0.82 ADAM17 (0.81) ADAM17MMP1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050215549-A1 TACE inhibitors MCCLURE KIM F 2005-09-29 US disclosed
EP-1104412-B1 TACE INHIBITORS PFIZER PROD INC (US) 2005-06-15 EP disclosed
US-20030181441-A1 TACE INHIBITORS McCLURE Kim (US) 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181441-A1 TACE INHIBITORS ADAMTS5, ADAMTS1, MMP2 ADAM17 22/4885MMP1 18/4885MMP13 35/4885
US-20050215549-A1 TACE inhibitors ADAMTS5, ADAMTS1, MMP2 ADAM17 19/4885MMP1 15/4885MMP13 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.